You just read:

Pan-Canadian Oncology Drug Review Recommendation Supports the Use of Tagrisso® (osimertinib) as the Standard of Care for T790M Mutated Non-Small Cell Lung Cancer

News provided by

AstraZeneca Canada Inc.

May 08, 2017, 07:59 ET